Patient characteristics, N = 44
| Characteristic . | No. . | % . |
|---|---|---|
| Median age, y (range) | 64 (49-86) | |
| Sex | ||
| Female | 14 | 32 |
| Male | 30 | 68 |
| No. of prior treatments, median (range) | 5 (1-15) | |
| Fludarabine refractory | 12 | 27 |
| Rai stage | ||
| I to II | 24 | 55 |
| III to IV | 20 | 45 |
| Serum β2M, median (range) | 4.3 (1.6-10.1) | |
| Bulky adenopathies | 17 | 39 |
| VH mutation status | ||
| Mutated | 4 | 9 |
| Unmutated | 29 | 66 |
| Not tested | 11 | 25 |
| FISH | ||
| 13q− | 5 | 11 |
| +12 | 6 | 14 |
| Normal | 7 | 16 |
| 11q− | 18 | 41 |
| 17p− | 8 | 18 |
| Characteristic . | No. . | % . |
|---|---|---|
| Median age, y (range) | 64 (49-86) | |
| Sex | ||
| Female | 14 | 32 |
| Male | 30 | 68 |
| No. of prior treatments, median (range) | 5 (1-15) | |
| Fludarabine refractory | 12 | 27 |
| Rai stage | ||
| I to II | 24 | 55 |
| III to IV | 20 | 45 |
| Serum β2M, median (range) | 4.3 (1.6-10.1) | |
| Bulky adenopathies | 17 | 39 |
| VH mutation status | ||
| Mutated | 4 | 9 |
| Unmutated | 29 | 66 |
| Not tested | 11 | 25 |
| FISH | ||
| 13q− | 5 | 11 |
| +12 | 6 | 14 |
| Normal | 7 | 16 |
| 11q− | 18 | 41 |
| 17p− | 8 | 18 |